NeuralStem

OverviewSuggest Edit

NeuralStem is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.

TypePublic
Founded1996
HQRockville, USMap
Websiteneuralstem.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)5(-54%)
Revenue (FY, 2018)$260 K
Share Price (Oct 2019)$1.3 (-1%)

Key People/Management at NeuralStem

James B. Scully

James B. Scully

Interim CEO & PAO
Karl Johe

Karl Johe

CSO
David Recker

David Recker

CMO
Thomas Hazel

Thomas Hazel

Senior Vice President, Research
Show more

NeuralStem Office Locations

NeuralStem has an office in Rockville
Rockville, US (HQ)
9700 Great Seneca Hwy
Show all (1)

NeuralStem Financials and Metrics

NeuralStem Revenue

NeuralStem's revenue was reported to be $260 k in FY, 2018
USD

Revenue (FY, 2018)

260.0k

Net income (FY, 2018)

(4.9m)

EBIT (FY, 2018)

(8.3m)

Market capitalization (17-Oct-2019)

3.4m

Closing stock price (17-Oct-2019)

1.3

Cash (31-Dec-2018)

5.8m
NeuralStem's current market capitalization is $3.4 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

110.0k10.4k16.2k260.0k260.0k

General and administrative expense

5.3m6.5m7.5m5.5m4.6m

Operating expense total

12.6m19.2m20.7m13.6m8.5m

Depreciation and amortization

244.7k
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.5k5.0k5.0k2.9k2.5k2.5k2.5k2.5k2.5k2.5k2.5k2.5k252.5k

General and administrative expense

1.7m1.5m2.0m1.4m1.7m1.8m3.2m1.4m1.3m1.6m1.2m1.2m1.3m

R&D expense

1.9m2.1m3.2m3.3m3.4m3.1m2.5m3.6m2.6m1.4m1.2m1.0m

Operating expense total

3.6m3.5m4.0m4.6m5.0m5.2m6.2m3.8m4.9m4.2m2.6m2.4m2.3m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

16.8m12.5m4.7m15.2m6.7m5.8m

Accounts Receivable

Inventories

Current Assets

17.6m28.2m13.5m20.9m12.4m6.5m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

16.4m15.2m11.9m13.6m8.6m13.1m7.6m11.1m5.7m6.4m9.1m9.7m7.1m

Current Assets

17.3m30.8m27.7m29.2m24.7m19.6m8.7m11.8m6.7m11.7m14.7m10.2m7.9m

PP&E

253.6k310.1k301.3k282.1k343.0k335.9k337.0k363.2k315.5k219.4k196.2k149.7k128.0k

Total Assets

19.2m32.6m29.4m30.8m26.4m21.1m10.2m13.3m8.5m13.3m16.2m11.5m9.2m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(19.8m)(22.6m)(20.9m)(21.1m)(15.7m)(4.9m)

Depreciation and Amortization

244.7k348.6k345.5k337.5k289.2k185.8k

Inventories

Accounts Payable

(116.7k)1.4m(1.0m)879.1k(1.5m)(37.0k)
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(16.5m)(12.7m)(4.5m)(5.1m)(10.5m)(16.1m)(6.6m)(10.5m)(15.7m)(12.2m)(12.4m)(2.1m)(2.8m)

Depreciation and Amortization

182.0k177.2k83.0k167.4k255.4k85.5k177.5k275.1k180.6k233.6k67.4k114.3k

Accounts Payable

(97.1k)465.6k2.4m2.1m(405.1k)(1.3m)1.2m955.2k1.0m(160.7k)(920.6k)293.1k(151.7k)

Cash From Operating Activities

(8.1m)(5.1m)(9.5m)(15.0m)(3.5m)(7.1m)(11.5m)(7.8m)(11.1m)(1.8m)(4.4m)
show all
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics

NeuralStem Online and Social Media Presence

NeuralStem's Trends

Embed Graph

NeuralStem News and Updates

October 03, 2019

Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)

GERMANTOWN, Md., Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced the adjustment of an options award that was previously...
September 24, 2019

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

GERMANTOWN, Md., Sept. 24, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic...
August 14, 2019

Neuralstem Reports Second Quarter 2019 Fiscal Results

GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June...
July 01, 2019

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

GERMANTOWN, Md., July 1, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open...
May 14, 2019

Neuralstem Reports First Quarter 2019 Fiscal Results

GERMANTOWN, Md., May 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, reported its financial results for the first quarter...
March 22, 2019

Neuralstem Reports Year End 2018 Fiscal Results

GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, today reported its financial results for the year ended December 31,…

 NeuralStem Frequently Asked Questions

  • When was NeuralStem founded?

    NeuralStem was founded in 1996.

  • Who are NeuralStem key executives?

    NeuralStem's key executives are James B. Scully, Karl Johe and David Recker.

  • How many employees does NeuralStem have?

    NeuralStem has 5 employees.

  • What is NeuralStem revenue?

    Latest NeuralStem annual revenue is $260 k.

  • What is NeuralStem revenue per employee?

    Latest NeuralStem revenue per employee is $52 k.

  • Who are NeuralStem competitors?

    Competitors of NeuralStem include InVivo Therapeutics, Pandion Therapeutics and IO Biotech.

  • Where is NeuralStem headquarters?

    NeuralStem headquarters is located at 9700 Great Seneca Hwy, Rockville.

  • Where are NeuralStem offices?

    NeuralStem has an office in Rockville.

  • How many offices does NeuralStem have?

    NeuralStem has 1 office.